Our Approach to Cancer Care is Like No Other

XCancer, formerly The Urology Cancer Center (UCC) &  XCancer Omaha, formerly GU Research Network, were founded in 2010 by Dr. Luke Nordquist, and rapidly rose to the highest ranks as an elite center in the U.S. for the treatment and innovative research for Prostate & Urologic Cancers (Kidney, Bladder, Testicular). Patients from more than 42 states, internationally, and patients referred from major centers such as Mayo Clinic, Johns Hopkins, and Memorial Sloan Kettering all call XCancer home for their care.

HOW DID WE GET HERE?

With degrees in both Pharmacy and Medicine from Creighton University, Dr. Luke completed his Internal Medicine training at the H. Lee Moffit Cancer Center in Tampa, FL & Oncology training at Memorial Sloan Kettering Cancer Center in NYC. His interest and dedicated research were in the field of Prostate Cancer and Immune Therapies.

In 2010, Dr. Luke opened XCancer with the sole purpose of creating a highly focused, highly compassionate, and highly cutting-edge cancer center dedicated only to Prostate & Urologic cancers.

He started in 2010 with 3 staff and 3 research clinical trials. Over ten years later, he has over 50 employees and has been an investigator on several hundred prostate & urologic cancers clinical trials which has led to the FDA approval of many life-saving treatments. XCancer has performed several first-in-the-world treatments on early-phase clinical trials and is considered a top site to perform the latest research for pharmaceutical companies that have novel cancer therapies. XCancer is often asked by major centers such as Duke, Cornell, and Sloan Kettering to partner in clinical trials because of our reputation for patient experience, patient volumes, and quality of work.

What Makes Us Different?

Why XCancer For Your Expert Second Opinion?

Not all board-certified Oncologists are the same. They have different training, different cancer interests, and different motivations. The majority of Oncologists spend their days treating ALL types of cancer.  In their typical clinic, they will treat patients with breast cancer, lung cancer, leukemias, lymphomas, colon cancer, prostate cancer, and more. The amount of knowledge that it takes to keep up with even one cancer type is expansive and keeping up with the latest information for all cancer types is borderline impossible.  Because of this vast mountain of information and rapidly changing treatment options, most oncologists can only provide standard-of-care treatments. That is good care, but it may be outdated and may not be your best care. In reality, it often limits your care.

Meet Dr. Luke Nordquist

Early in his career, Dr. Luke Nordquist realized the need for a cancer center dedicated solely to the treatment and research of Prostate & Urologic cancers. In 2010, Dr. Luke founded XCancer, formerly the Urology Cancer Center & GU Research Network in Omaha, NE. This cancer center has rapidly elevated to the level of an elite center of excellence for Prostate & Urologic Cancers. XCancer was the first cancer center in the U.S. to receive government NCQA recognition for its Patient-Centered Oncology Medical Home Program and the first cancer center in its region to receive QOPI certification from the American Society of Clinical Oncology for its excellence in quality cancer care.

Through its expert focus, efficiencies, and expanding network, XCancer & XCancer Omaha Research has become recognized globally by thought leaders, pharmaceutical companies, and patients as a leader in drug development through Phase 1-4 clinical trials. Dr. Luke has been the Principal Investigator on several hundred urologic cancer studies including several first-in-world treatments at XCancer. Dr. Luke serves as an expert on ASCO’s guidelines panel for Advanced Prostate Cancer.  

Dr. Luke started his career with a degree in Pharmacy followed by a Doctorate of Medicine, both from Creighton University. He completed a residency in Internal Medicine at the University of South Florida / H. Lee Moffitt Cancer Center in Tampa, FL. This was followed by a Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center & Medical College of Cornell in New York City. His clinical and research focus during his training was in prostate cancer and immune therapies.  

Dr. Luke has surfaced as a leader in the field of radiopharmaceuticals for the treatment of prostate cancer. He has conducted several clinical trials for agents such as Ra223 and Lu177. He has been chosen as one of three sites in the U.S. for two phase 1 studies utilizing Ac225 and Th227. He enrolled the first patient globally on the VISION study with Lu177 for advanced prostate cancer and accrued over 50 of the 800 total global patients for that study.

Dr. Luke is also the CEO of the XCancer Research Network. Using experience and tools developed and realized in the XCancer Omaha Research program, XCancer enables, oversees, and helps conduct clinical trials in community cancer centers across the U.S. This network provides much-needed access to potentially life-saving clinical trials to more cancer patients across the U.S. He realizes the vast research potential Community Cancer Centers hold, given they care for 80% of the U.S. cancer population but currently only enroll 2% of their patients on clinical trials. XCancer is currently working with community cancer centers. Many of these centers have the facilities, credentials, and ability to participate in radiopharmaceutical clinical trials.

Dr. Luke knows cancer patients are faced with many tough decisions and heavy burdens. He believes extensive patient education at an understandable level is at the center of excellent care and helping patients make their best decisions. Dr. Luke has served on the ASCO Government Relations Committee and is continually learning from and advocating for his patients both locally and nationally on the challenges they face and helping reduce their burdens.

Make Your Second Opinion An Expert Opinion